Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2007-01-09
2007-01-09
Witz, Jean C. (Department: 1651)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C435S180000, C514S002600
Reexamination Certificate
active
10312685
ABSTRACT:
Whole blood assays and kits are described for evaluating dosage of factor VIIa or activated protein C, as well as for monitoring responsiveness to factor VIIa or activated protein C.
REFERENCES:
patent: 5091304 (1992-02-01), La Duca et al.
patent: 5217705 (1993-06-01), Reno et al.
patent: 5318910 (1994-06-01), LaDuca
patent: 5580560 (1996-12-01), Nicolaisen et al.
patent: 5788965 (1998-08-01), Berkner et al.
patent: 5817788 (1998-10-01), Berkner et al.
patent: 5824639 (1998-10-01), Berkner
patent: 5833982 (1998-11-01), Berkner et al.
patent: 5861374 (1999-01-01), Berkner et al.
patent: 5986065 (1999-11-01), Wong et al.
patent: 5990079 (1999-11-01), Wolf et al.
patent: 6017882 (2000-01-01), Nelsestuen
patent: 6037452 (2000-03-01), Minamino et al.
patent: 6110721 (2000-08-01), Gibbs et al.
patent: 6214333 (2001-04-01), Zoldhelyi et al.
patent: 08092294 (1996-04-01), None
patent: WO 91/09125 (1991-06-01), None
patent: WO 94/29370 (1994-12-01), None
patent: WO 97/11957 (1997-04-01), None
patent: WO 98/32466 (1998-07-01), None
patent: WO 99/20767 (1999-04-01), None
patent: WO 00/66753 (2000-11-01), None
patent: WO 01/02439 (2001-01-01), None
patent: WO 01/58935 (2001-08-01), None
patent: WO 02/02764 (2002-01-01), None
patent: WO 02/03075 (2002-01-01), None
Webster's II New Riverside Dictionary (1984) (Houghton-Mifflin: Boston, MA) p. 667.
Towne et al. “Abnormalities of the fibrinolytic system as a cause of upper extremity ischemia: a preliminary report,” J. Vascular Surgery, (1988) 7(5): 661-666 (abstract only).
McKean et al. “Future therapies for the prevention and treatment of venous and arterial thrombosis,” Expert Opinion of Invest. Drugs (1998) 7(5): 687-690.
Ambrose et al., “Evaluation of the TAS Analyzer and the Low-Range Heparin Management Test in Patients Undergoing Extracorporeal Membrane Oxygenation,”Clin. Chem., 2001, 47(5):858-866.
Banner et al., “The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor,”Nature, 1996, 380:41-46.
Beauchamp et al., “A New Procedure for the Synthesis of Polyethylene Glycol-Protein Adducts; Effects on Function, Receptor Recognition, and Clearance of Superoxide Dismutase, Lactoferrin, and α2-Macroglobulin,”Analyt. Biochem., 1983, 131:25-33.
Dahlbäck, “The Protein C Anticoagulant System: Inherited Defects as Basis for Venous Thrombosis,”Thromb. Res., 1995, 77:1-43.
Furie and Furie, “The Molecular Basis of Blood Coagulation,”Cell, 1988, 53:505-518.
Harker et al., “Antothrombotic Strategies Targeting Thrombin Activities, Thrombin Receptors and Thrombin Generation,”Thromb. Haemost., 1997, 78:736-741.
Hedner and Falch, “Recombinant Activated Factor VII in the Treatment of Bleeding Episodes in Patients With Inherited and Acquired Bleeding Disorders,”Transfus. Med. Rev., 1993, 7(2):78-83.
Lee et al., “Prolonged Circulating Lives of Single-Chain Fv Proteins Conjugated with Polyethylene Glycol: A Comparison of Conjugation Chemistries and Compounds,”Bioconjugate Chem., 1999, 10:973-981.
Luo et al., “Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein,”Nature, 1997, 386:78-81.
Manfioletti et al., “The Protein Encoded by a Growth Arrest-Specific Gene (gas6) Is a New Member of the Vitamin K-Dependent Proteins Related to Protein S, a Negative Coregulator in the Blood Coagulation Cascade,”Mol. Cell. Biol., 1993, 13(8):4976-4985.
McDonald et al., “Comparison of Naturally Occurring Vitamin K-Dependent Proteins: Correlation of Amino Acid Sequences and Membrane Binding Properties Suggests a Membrane Contact Site,”Biochemistry, 1997, 36:5120-5127.
Monroe et al., “Platelet activity of high-dose factor VIIa is independen of tissue factor,”Br. J. Haematol., 1997, 99:542-547.
Muir and Kent, “The chemical synthesis of proteins,”Curr. Opin. Biotechnol., 1993, 4:420-427.
Nelsestuen et al., “Enhancement of Vitamin-K-Dependent Protein Function by Modification of the γ-Carboxyglutamic Acid Domain: Studies of Protein C and Factor VII,”Trends Cardiovasc. Med., 1999, 9:162-167.
Nelsestuen et al., “Vitamin K-Dependent Proteins,”Vitam. Horm., 2000, 58:355-389.
Shah et al., “Manipulation of the membrane binding site of vitamin K-dependent proteins: Enhanced biological function of human factor VII,”Proc. Natl. Acad. Sci. USA, 1998, 95:4229-4234.
Shearwater Polymers, Inc., 2000, Catalog, p. 11.
Shearwater Polymers, Inc., 2000, Catalog, p. 20.
Shearwater Polymers, Inc., 2000, Catalog, p. 34.
Shearwater Polymers, Inc., 2000, Catalog, p. 41.
Shen et al., “Enhancement of Human Protein C Function by Site-directed Mutagenesis of the γ-Carboxyglutamic Acid Domain,”J. Biol. Chem., 1998, 273(47):31086-31091.
Sørensen et al., “Incorporation of an Active Site Inhibitor in Factor VIIa Alters the Affinity for Tissue Factor,”J. Biol. Chem., 1997, 272(18):11863-11868.
Spanier et al., “Heparinless Cardiopulmonary Bypass with Active-Site Blocked Factor IXA: A Preliminary Study on the Dog,”J. Thorac. Cardiovasc. Surg., 1998, 115:1179-1188.
Vallette et al., “Construction of mutant and chimeric genes using the polymerase chain reaction,”Nucleic Acids Research, 1989, 17(2):723-733.
Hanley Susan
Regents of the University of Minnesota
Witz Jean C.
LandOfFree
Methods for detecting activity of clottings factors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for detecting activity of clottings factors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for detecting activity of clottings factors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3815887